Evidence map›Paper›PMID 21653738›Full record

ArticleMolecular & cellular proteomics : MCP2011

High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations.

Maja Pucić, Ana Knezević, Jana Vidic, Barbara Adamczyk, Mislav Novokmet, Ozren Polasek, Olga Gornik, Sandra Supraha-Goreta, Mark R Wormald, Irma Redzić and 9 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 290 papers.

0numbers the graph read from it
0cells of the map it votes in
290citing papers in PubMed
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

290 citing papers in PubMed, 526 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

230 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 10 institutions in 6 countries.

Maja PucićGenos Ltd., Glycobiology Division, Planinska 1, 10000 Zagreb, Croatia.
Ana Knezević
Jana Vidic
Barbara Adamczyk
Mislav Novokmet
Ozren Polasek
Olga Gornik
Sandra Supraha-Goreta
Mark R Wormald
Irma Redzić
Harry Campbell
Alan Wright
Nicholas D Hastie
James F Wilson
Igor Rudan
Manfred Wuhrer
Pauline M Rudd
Djuro Josić
Gordan Lauc
Genos (Croatia) · HRUniversity of Zagreb · HRMRC Human Genetics UnitNational Institute for Bioprocessing Research and Training · IEUniversity of Edinburgh · GBUniversity of Split · HRBIA Separations (Slovenia) · SILeiden University Medical Center · NLUniversity of Oxford · GBUniversity of Rijeka · HR

Funding

UCP2 expression in colon cancerP20RR017695 · NCRR · RHODE ISLAND HOSPITAL (PROVIDENCE, RI) · PI CHIN, Y. EUGENE · 2002 to 2011
$15.0M
Chief Scientist Office CZB/4/710Chief Scientist Office CZB/4/728Medical Research Council MC_PC_U127561128Medical Research Council MC_U127561128NCRR NIH HHS P20 RR017695NCRR NIH HHS P20RR017695
6 · The paper itself

Abstract

All immunoglobulin G molecules carry N-glycans, which modulate their biological activity. Changes in N-glycosylation of IgG associate with various diseases and affect the activity of therapeutic antibodies and intravenous immunoglobulins. We have developed a novel 96-well protein G monolithic plate and used it to rapidly isolate IgG from plasma of 2298 individuals from three isolated human populations. N-glycans were released by PNGase F, labeled with 2-aminobenzamide and analyzed by hydrophilic interaction chromatography with fluorescence detection. The majority of the structural features of the IgG glycome were consistent with previous studies, but sialylation was somewhat higher than reported previously. Sialylation was particularly prominent in core fucosylated glycans containing two galactose residues and bisecting GlcNAc where median sialylation level was nearly 80%. Very high variability between individuals was observed, approximately three times higher than in the total plasma glycome. For example, neutral IgG glycans without core fucose varied between 1.3 and 19%, a difference that significantly affects the effector functions of natural antibodies, predisposing or protecting individuals from particular diseases. Heritability of IgG glycans was generally between 30 and 50%. The individual's age was associated with a significant decrease in galactose and increase of bisecting GlcNAc, whereas other functional elements of IgG glycosylation did not change much with age. Gender was not an important predictor for any IgG glycan. An important observation is that competition between glycosyltransferases, which occurs in vitro, did not appear to be relevant in vivo, indicating that the final glycan structures are not a simple result of competing enzymatic activities, but a carefully regulated outcome designed to meet the prevailing physiological needs.

Indexed as

High-Throughput Screening AssaysAdolescentAdultAgedAged, 80 and overFemaleFucoseGenetic VariationGlycomicsGlycoproteinsGlycosylationHumansImmunoglobulin GMaleMiddle AgedModels, MolecularanthranilamideFucoseGlycoproteinsglycosylated IgGImmunoglobulin Gortho-AminobenzoatesPeptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine AmidasePolysaccharides

Identifiers

PMID21653738
PMCPMC3205872
OpenAlexW2140723605

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.